Pharmacovigilance in the Modern Era

HISTORY

The disciplinary field of pharmacovigilance (PV) is frequently associated with pharmacological and epidemiological research. This is due to the fact that it is primarily regarded as a discipline that focuses on evaluations in the area of medication safety and approval (Rocca et al., 2019). Nonetheless, Rocca et al. (2019) acknowledge that this field has produced several novel insights concerning epidemiology and epistemology. However, the development of new approaches, procedures, and evidence standards to facilitate the application of risk assessment is becoming more and more important.

 The initial systems for pharmaceutical control: The sulfonamide situation in 1932, Domagk (1895–1964) proved that sulfonamides were effective in treating streptococci. Following the establishment of the trademark patent Protonsil in 1935, which made it possible to market the first medication containing this active ingredient, the first sulfonamide was produced and sold (Morales and Bosch, 2007). The first sulfonamides' effectiveness was widely reported in the media, which had a significant social impact. In actuality, the favorable perceptions of the drug were conditioned by an imaginary factor. The New York Times reported in 1936 that President Roosevelt's son had been treated with Prontylin, a dispensing form of Protonsil, following his hospital admission due to a severe tonsil infection caused by Streptococcus (Morales and Bosch, 2007). The Food and Drug Administration (FDA) became aware of the increasing regulatory issue caused by the growth of sulfonamides due to the commercial success of this medication (Cooper, 2002).

Pharmaceutical control system maturity: Thalidomide as an example Alpha-phthalimido-glutarimide, or thalidomide, was successfully obtained in 1954 by the German company Chemie Grünenthal. This medication was used in 1957 to treat anxiety, insomnia, nausea, and vomiting in pregnant women. It was categorized as a sedative and hypnotic (Martínez-Frías, 2012). Following thalidomide exposure, the first isolated case of phocomelia was reported in 1956. Over the next five years, 3,000 cases of dysmelias, congenital malformations like amelias, phocomelia, or absence/hypoplasia of the thumb or fingers, among other conditions, were progressively reported globally (Papaseit et al., 2013). However, Florence (1960) reports in a brief letter to the British Medical Journal that patients receiving thalidomide for long periods of time (8 months to 2 years) complained of the following side effects: (1) Paresthesia affecting first the feet and then the hands. (2) The extremities are cold, and the toes are noticeably paler. (3) Slight ataxia on occasion. (4) Leg muscle cramps during the night.

The adverse effects decreased when the patients stopped taking the drug and the treatment was discontinued. Leslie Florence became suspicious of thalidomide's toxicity as a result. A series of letters about the effects of thalidomide were subsequently published in The Lancet magazine in January 1962. Lenz (1962) signed the first of these letters, which described 52 children who had deformities as a result of their mothers consuming this substance while they were pregnant. However, Lenz notes in this letter that the author attended a conference on November 18, 1961, where the topic of this substance's role in the development of human malformations was previously discussed. Another letter by Pfeiffer and Kosenow (1962) was published in the same issue of The Lancet. In it, he stated that there was a strong statistical correlation between the use of thalidomide during the first trimester of pregnancy and the development of defects. Thalidomide is emphasized in the third letter, which is signed by Hayman (1962), the managing director of the Distillers Company, and starts by thanking them for the expressions of gratitude they received. He continues by saying that it is especially challenging to determine the negative effects of this substance because of the scant data and official statistics. The objective data from the different researchers demonstrated that thalidomide was not as safe as it was claimed to be, regardless of one's personal opinion of Hayman's writing.

Fig No 1 : Development Timeline of Pharmacovigilance

 METHODS USED IN PHARMACOVIGILANCE -

The actions carried out in the name of pharmacovigilance can be broadly separated into three categories: regulatory, both academia and industry. Pharmacovigilance that is regulated is motivated by the goal of giving medications a beneficial effect harm profile to the general public. Several issues pertaining to the topic of regulatory post-marketing surveillance will be covered in this background, then an explanation of the techniques employed to identify novel ADRs and an analysis of the benefits and drawbacks of each approach

1. Clinical trial data insufficient to evaluate drug risk

Inadequate clinical trial data to assess medication risk Currently, the primary technique for obtaining data on a medication in the pre-marketing stage is to carry out a clinical trial. There are three types of pre-marketing clinical trials stages. Phase III research frequently uses double blind randomization controlled trials, which are thought to be the most methodical approach to establishing whether a cause-and-effect. There is a connection between an outcome and a treatment.But when it comes to keeping an eye on a medication's safety, The design of this study is not ideal. Because of the small number of patients taking part, it is typically not feasible to determine which ADRs are infrequent. The comparatively brief it is challenging to identify ADRs due to the length of clinical trials with an extended latency. Clinical trials also have the drawback of the population used to test drugs. The traits of the participants don't always match the features of the population that it will eventually be utilized; therefore, it could be challenging to extrapolate the findings from clinical trials to the general public at large. This is particularly true for women and the elderly or for members of a minority ethnic group. To investigate uncommon ADRs, long-latency ADRs, and ADRs in particular populations, it is crucial to closely monitor the medication during the post-marketing phase.

2. Spontaneous reporting

There are two types of descriptive research: Intense monitoring and impromptu reporting—will be talked about here. Analytical research can be carried out with a range of methods, such as case-control studies, clinical trials and cohort studies. To be able tocarry out case-control and retrospective cohort studies, data which have been routinely and reliably gathered must be accessible. To give an illustration of such studies, we outline two databases from Europe here. Frequently employed in analytical research, the General Practitioners UK Research Database (GPRD) and the PHARMO The Netherlands' Record Linkage System.Unplanned reporting. A 1961 letter from the Australian doctor WG The Lancet published McBride. In this correspondence, he revealed his finding that infants whose mothers had utilized thalidomide during pregnancy were born with congenital anomalies more frequently than infants who had not been thalidomide exposure during pregnancy. In the years ahead, it became apparent that thousands of newborns had been born with limb deformities brought on by the mother's use of thalidomide. To stop a similar catastrophe from systems were established worldwide with the goal of controlling and keeping an eye on drug safety. Systems for spontaneous reporting (SRS) were developed, and  these are now the main way that post marketing data regarding medication safety. The primary SRS's role is to identify new signals early on. uncommon and dangerous ADRs. A system of spontaneous reporting permits doctors and, more frequently, pharmacists and patients to notify a pharmacovigilator of any suspected adverse drug reactions. lance center. The pharmacovigilance task center is to gather, evaluate, and disseminate the reports stakeholders of the possible danger when indications of new ADRs occur.

3. Data minimizing in spontaneous reporting

In the past, signal detection in spontaneous reporting has mainly occurred on the basis of case-by-case analyses of reports. In recent years, however, data mining techniques have become more important. The term ‘data mining’ refers to the principle of analysing data from different perspectives and extracting the relevant information. Algorithms are often used to determine hidden patterns of associations or unexpected occurrences i.e. signals in large data-bases. Although the methodology of the various data mining methods applied in pharmacovigilance differ, they all share the characteristic that they express to what extent the number of observed cases differs from the number of expected cases. Several approaches of data mining are currently in use. Proportional reporting ratios (PPRs), compare the proportion of reports for a specific ADR reported for a drug with the proportion for that ADR in all other drugs. The calculation is analogous to that of relative risk. Using the same information, it is also possible to calculate a ‘reporting odds ratio’. The Bayesian confidence propagation neural network (BCPNN) method is used to highlight dependencies in a data set. This approach uses Bayesian statistics implemented in a neural network architecture to analyse all reported ADR combinations.

4. Intensive monitoring

During the late 1970s and early 1980s, a novel type of active New Zealand developed surveillance (the Intensive Medicines Monitoring Programme) and the United Kingdom (Prescription Monitoring events). These rigorous monitoring systems make use of prescription information to identify drug users.The medication's prescriber is questioned about any side effects taking place while the drug under observation is being used. These to find new signals, data are gathered and examined. The these intensive monitoring systems' methodology has been thoroughly discussed elsewhere . Intensive monitoring is based on a non-interventional observational cohort, setting it apart from spon simultaneous reporting, as the former merely keeps an eye on chosen medications over a specific time frame. Through its with its non-interventional nature, close observation offers actual clinical data that doesn't involve inclusion or criteria for exclusion during the time of collection. It is independent of the type of criteria used for selection and exclusion that define clinical trials, removing the need for selection prejudice. The methodology's foundation is another advantage upon event monitoring and, as a result, can recognize Finding signs of events that weren't necessarily suspected as the medication under study's adverse drug reactions. Intense Programs for monitoring also make it possible for the occurrence of adverse events to be calculated, allowing for quantification of the possibility of specific ADRs.

5. Database study

A study must be conducted in order to test a hypothesis. The research can be carried out in a number of ways, including cohort studies and case-control studies. The Power considerations are one of these methods' limitations. and research methodology. For the purpose of conducting retro comprehensive case-control and cohort studies, information that has been gathered in a dependable and consistent manner must be accessible. The GPRD, or General Practice Research Database as well as the PHARMO Record Linkage System, which will explained in more detail in the sections that follow, were selected because they stand for two distinct kinds of databases from Europe. Additional database and record linking Systems are accessible for study in both Europe and as well as in North America .

6. Pharmo

Early in the 1990s, the PHARMO record-linking system was created in the Netherlands. Links to PHARMO hospital and community pharmacy data within a particular region based on the patient's gender, birthdate, and GP code. Drug-dispensing records are now part of the system from hospital discharge records and neighborhood pharmacies of roughly two million Dutch citizens. The information the collection dates back to 1987 and is longitudinal. Additional PHARMO has recently been connected to additional data, including as population surveys, primary care data, laboratory and genetic information, accident and cancer databases, and mortality statistics and financial results. The system has clearly defined denominator data that permits prevalence and lence estimates and is reasonably priced due to the fact that Databases are linked and utilized. The database PHARMO is utilized for case-control studies, follow-up research, and other analytical epidemiological research to assess medication effects that are induced. The database has previously been utilized for research on drug use, treatment compliance, ADRs and economic impact .

ADVERSE DRUG REACTION IN PHARMACOVIGILANCE -

The World Health Organization defines pharmacovigilance as "the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems."

According to this framework, one of the most important issues in contemporary healthcare is adverse drug reactions, or ADRs. Unintentional, detrimental reactions to drugs that happen at typical therapeutic dosages are known as adverse drug reactions (ADRs), and they are a significant global cause of morbidity, mortality, and financial burden.

The severity of ADRs is demonstrated by recent worldwide data. To illustrate the scope of the issue, pharmacovigilance databases like the FDA Adverse Event Reporting System reported nearly 175,000 deaths and over 1.25 million serious adverse events in a single year.

Classification of Adverse Drug Reaction –

Table no 1 : Frequency of occurrence based on the type of adverse drug reaction

Types Of Adverse Drug Reactions –

Table no 2 : Types of adverse drug reaction

CLINICAL TRIALS –

• Clinical Research: The scientific study carried out to comprehend, avoid, identify, or cure human illnesses and ailments methodical investigation of people, frequently via clinical trials, to produce evidence-based information that can enhance patient care and expand medical knowledge.The creation of novel medical treatments, therapies, and healthcare approaches depends heavily on research.
• Preclinical Trial: An essential early stage of drug development is preclinical trials. In order to collect information on the drug's safety profile, pharmacokinetics (drug absorption, distribution, metabolization, and excretion), and pharmacodynamics (drug biological effects). The objective is to make sure the medication has enough potential and doesn't present intolerable risks effectiveness prior to it.
• Clinical trials: are a particular type of clinical research that is intended to assess the effectiveness and safety of medical interventions, such as medications, equipment, therapies, and preventative measures. These experiments are carried out in stages, each of which serves a specific goal in the investigation process.

Introduction to Pre-Clinical Trials

Because preclinical research assesses a target compound's safety, efficacy, and potential side effects, it is crucial to the process of discovering and creating new medications. intervention before any testing on humans. These studies help researchers make informed decisions about the progress of clinical trials, allowing for the development of innovative and effective therapies that can improve patients' lives everywhere. In the preclinical phase, laboratory-based tests and experiments are typically conducted using either in vivo or in vitro testing.

Preclinical study types include:

 1. In vitro studies: which are experiments carried out in lab settings using organs, tissues, or cells (such as "organ-on-a-chip" systems or cell cultures).

 2. In Silico Research: Using computer simulations and modeling to forecast how a drug may act in the human body, improving research design and minimizing animal testing.

 3. In Vivo Research: Examining living things, mainly animal models usually two mammalian species—one rodent and one non-rodent, like dogs and mice to evaluate the effects of a medication on an entire biological system .

Introduction of Clinical Trials -

Overview of Clinical Trials: A clinical trial is a methodical procedure designed to determine the effectiveness and safety of a medication or tool for diagnosing, treating, or preventing a medical condition. Clinical investigation comprises several stages, such as phase 0 (micro-dosing studies), phase 1, phase 2, phase 3, and phase 4. Phases 0 and 2 are referred to as exploratory trial phases, while phase 1 is known as the non- Phase 3 is referred to as the therapeutic confirmatory phase, Phase 4 is called the post-approval or post-marketing surveillance stage. Clinical trials are a particular type of clinical research intended to assess the effectiveness and safety of medical interventions, such as medications, equipment, therapies, and preventative measures.

Phases of Clinical Trials -

• Phase I: Concentrates on evaluating the dosage range, safety, and possible adverse effects of the intervention. usually entails a small number of healthy volunteers.
• Phase II: Involves a wider range of individuals, including those who suffer from interest. Evaluating the intervention's efficacy and safety is the aim.
• Phase III: Extensive studies that contrast the novel intervention with the current therapies. These studies offer more thorough data on efficacy and safety and are essential for getting regulatory approval.
• Phase IV: Post-marketing research carried out following approval of the intervention and are accessible to the general public. These studies track the long-term safety of the intervention and efficacy in a broader, more varied population.

Fig no 2: Process of clinical trials

Regulatory bodies that approves Clinical Trials –

1. Ethics Committees / Institutional Review Boards (IRBs)

• Protect the rights, safety, and welfare of participants.
• Review the study protocol, informed-consent documents, and risk–benefit balance.
• Mandatory in all countries before a trial can start.

2. National Regulatory Authorities

These agencies ensure that the trial meets scientific, safety, and quality standards. Examples:

• United States: Food and Drug Administration (FDA)
• European Union: European Medicines Agency (EMA) + national authorities

• United Kingdom: Medicines and Healthcare products Regulatory Agency
• (MHRA)  Canada: Health Canada
• Australia: Therapeutic Goods Administration (TGA)
• India: Central Drugs Standard Control Organization (CDSCO)
• Japan: Pharmaceuticals and Medical Devices Agency (PMDA)

ROLE OF HEALTHCARE PROFESSIONALS IN PHARMACOVIGILANCE -

Clinicians' role in drug safety and pharmacovigilance:

By identifying, treating, and reporting adverse drug reactions (ADRs) to national  pharmacovigilance centers (NPCs), clinicians play a critical role in preventing ADRs. Therapeutic reasoning and the right drug selection for each patient are necessary for the safe and sensible prescription of medications . Age, medication errors, polypharmacy, and patient-specific risk factors like comorbidities can all raise the risk of adverse drug reactions (ADRs).

Roles of national pharmacovigilance centre

Coordinating national ADR monitoring programs is NPCs' primary responsibility. This typically entails keeping an eye on, looking into, and evaluating ADR reports that are obtained from medical professionals and product license holders .

Fig No 3 : Role of Pharmacovigilance.

Product license holders are accountable for their products on the market, so they must report all pertinent safety information and adhere to post-marketing regulations. This includes responding quickly to requests for data needed to perform a benefit-risk analysis so that the proper regulatory measures can be implemented. The Council for International Organizations of Medical Sciences (CIOMS) and the International Conference on Harmonization (ICH) offer scientific recommendations for pharmacovigilance and risk management of pharmaceuticals at every stage of their life cycle, from preclinical and clinical development to post-marketing . Pharmaceutical companies can report suspected adverse drug reactions (ADRs) using the CIOMS form, which follows a standard reporting procedure that has been proven to be beneficial and efficient .

 In addition to handling product defect reports, some NPCs may have portfolios that include cosmetics and personal hygiene items. For instance, the Center for Food Safety and Applied Nutrition's Adverse Event Reporting System, a public database of adverse events pertaining to foods, dietary supplements, and cosmetics, was established by the US Food and Drug Administration in 2016 .

CROSSROADS OF ANIMAL MEDICINES ( VETERINARY PHARMACOVIGILANCE ) -

With mounting evidence that veterinary medications are being used recreationally and in illegal drug markets, their abuse has become a major public health concern. This study used a variety of techniques, such as social media analysis, pharmacovigilance data approaches, and a systematic literature review, to look into veterinary medication abuse.

Techniques: 28 veterinary medications, mainly α-2 and β-2 adrenergic receptor agonists, GABAergic modulators, opioid receptor agonists, NSAIDs, and NMDA receptor antagonists, were found to be abused by humans in a systematic review of 66 articles. 38,756 adverse events were retrieved from a pharmacovigilance analysis of 21 veterinary medications using the FAERS database. Themes associated with misuse trends were examined in a netnographic dual-method analysis of Reddit discussions.

Outcomes: Veterinary medications were abused for recreational purposes, pain management, bodybuilding, weight loss, and stress-related self-medication. Inhalation, oral, and parenteral administration were common methods. Affordability, accessibility, and the simplicity of getting several prescriptions were among the driving forces. Levamisole, pentobarbital, and xylazine were among the most dangerous drugs, according to FAERS analysis, which showed 9566 fatalities. Ninety percent of cases showed signs of polysubstance use. Emerging abuse of xylazine, carfentanil, medetomidine, pentobarbital, phenylbutazone, and acepromazine was discovered through netnography.

In order to address the risks of overdose, dependence, and illicit drug adulteration, this study highlights the growing misuse of veterinary medications and the necessity of increased vigilance in healthcare and public health policy.

CASE STUDY : SAFETY AND REACTOGENICITY OF BNT162b2 COVID-19 VACCINE –

A substantial amount of safety data was produced by the clinical development  programs for coronavirus disease 2019 (COVID-19) vaccines, including BNT162b2, the subject of this review. Strong efficacy and short-term safety data (up to two months of follow-up post-primary schedule for BNT162b2, in accordance with regulatory guidance) served as the foundation for the initial approvals.  These approvals were modified to include a booster dose based on a 2.6-month follow-up after the BNT162b2 booster. Six Following approval, vaccine producers carried out clinical trials and worked with regulatory bodies and other groups to monitor longer-term safety through post-marketing pharmacovigilance initiatives. This post-authorization safety data soon outpaced the amount and scope of data produced by clinical trials. In addition to independent clinical and real-world trials in special populations and with various vaccination regimens, which validated the safety profile seen in clinical trials, permitted analysis of real-world practice patterns, and produced an unprecedented level of transparency, this was supported by real-world data from nations starting mass vaccination programs.

As soon as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, it became apparent that vaccines were urgently needed to combat the rapidly spreading pandemic. Several stakeholders worked together to accelerate vaccine development, authorization, and roll-out while upholding strict clinical trial standards.

The use of novel vaccine technologies with shorter design-to-production times, increased funding and collaboration, at-risk investment in commercial production from manufacturers prior to approval, accelerated regulatory procedures, and accelerated review timelines all contributed to the compression of vaccine clinical development timelines. Additionally, compared to typical vaccine development timelines, high infection rates and participant willingness to participate in clinical trials resulted in faster study completion and enrollment. Rapid production and scale-up of messenger RNA (mRNA) vaccines were made possible by pre-existing manufacturing processes. 1 As a result, compared to other vaccines, like influenza, development and commercialization timelines were significantly shorter, and all pathway steps necessary for regulatory approval were completed.

As booster doses and variant-adapted bivalent vaccines have been created and introduced to the market, the continuous emergence of new SARS-CoV-2 variants has prompted additional generation of safety data for mRNA vaccines.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both committed additional resources to facilitate the quick development and approval of vaccines. 7 While requiring manufacturers to provide additional vaccine data from clinical settings for thorough review, the FDA EUA pathway made COVID-19 vaccines rapidly accessible to the public in an emergency pandemic setting. 7 In a similar vein, the EMA accelerated its evidence appraisal procedure by implementing rolling review stages, which enabled regulators to obtain and examine the data as soon as they were made available. In order to accelerate deadlines while maintaining the development process, regular communication between manufacturers, regulatory bodies, and other stakeholders was crucial. Regulators were able to evaluate marketing authorization applications more quickly thanks to increased familiarity with the data and prearranged opportunities for sponsor/regulator conversations. 3 On December 21, 2020, the European Commission initially authorized BNT162b2 for conditional marketing.

Development in children

A clinical trial was conducted with participants aged 6 months to 11 years to evaluate pediatric age-related doses of BNT162b2 after the vaccine was approved for adult populations. Two doses of BNT162b2 (10 μg, 20 μg, or 30 μg) were given to the cohort of children aged 5 to 11 in the Phase I section (NCT04816643). The 10 μg dose was chosen for additional evaluation in the Phase II/III section due to a higher frequency of fever with the higher doses and because the neutralizing antibody profiles of the 10 μg and 20 μg doses were similar. 36. Participants in the cohort of children aged 6 months to 4 years were given either 10 μg or 3 μg of BNT162b2. The 3 μg dose was chosen for additional evaluation due to a higher frequency and more severe reactogenicity to the 10 μg dose compared to the 3 μg dose, as well as neutralizing antibody profiles across dose levels that were comparable to those seen in older age groups.

The majority of local and systemic reactions in a cohort of 3,013 children aged 6 months to 4 years who received BNT162b2 were mild to moderate in intensity, and there were no reports of Grade 4 local reactions. There were no fatalities, the frequency of adverse events (AEs) was comparable between BNT162b2 and placebo recipients, and few participants were discontinued as a result of AEs. 37.

ROLE OF PHARMACOVIGILANCE IN INDIA –

December 1961 saw the official introduction of pharmacovigilance (PV) with the release of a letter (case report) published in the Lancet by Australian physician W. McBride, who initially suspected a causal connection between thalidomide, a medication used during pregnancy, and severe fetal abnormalities (phocomelia) Pregnancy: Thalidomide was administered to expectant mothers as a sedative and antiemetic. Within the World Health Organization (WHO) advertised the "Programme for International Drug A pilot project called "Monitoring" sought to centralize global data on adverse drug reactions (ADRs). Within Specifically, the "WHO Programme's" primary goal was to determine the earliest potential PV signals. A group of French pharmacologists coined the term PV in the middle of the 1970s.Toxicologists should specify the actions that support "The assessment of the risks of side effects."possibly connected to medication therapy . PV is the science of gathering, tracking, investigating, evaluating, and assessing data from medical professionals and patients regarding the negative consequences of drugs, biological products, blood products, herbal remedies, vaccines, medical equipment, and complementary and traditional medicines with a view to discovering fresh data regarding product-related risks and avoiding injury to patients. The difficulty of preserving public trust while optimizing drug safety has grown more intricate. Biotechnology and pharmaceutical firms must not only monitor, as well as proactively assess and control medication risk over the course of a product's lifecycle, from creation to the post-market

Scope of pharmacovigilance in india :

Since the 1972 WHO technical report, the field of PV has advanced significantly, and it continues to be a vibrant scientific and clinical field. Overcoming the obstacles has been crucial of the growing variety and effectiveness of pharmaceutical and biological medications, such as vaccines, which have an unavoidable and occasionally unpredictable risk of side effects. However, there is a lower chance of injury when medications are administered by a qualified medical professional and by patients who are aware of and accountable for their medications. When unfavorable effects and toxicity manifest, especially when previously unidentified in connection with the medicine, it is crucial that they are evaluated and effectively conveyed to a group of people who possesses the expertise to understand the data This is PV's function, which has already been accomplished. However, more is needed to incorporate the field into clinical practice and public policy.

Fig No 4 :  A typical pharmacovigilance setup

Framework of New Program

The new program's framework the IPC center is dedicated to creating India's own drug information and adverse drug reaction database so that India won't need to rely on information from other nations to make decisions about to the suspension and prohibition of drugs. India currently lacks a robust database on ADRs and must rely on data from Western nations. Thus far, just 2823 ADRs have been documented since September 2010 under the current PVPI, which is insufficient to generate any significant conclusion associated with a specific signal.

Table No 3: Chronological Developments in PV

It is anticipated that all hospitals, clinics, educational institutions, and public health programs across the nation, both public and private, will participate in the PVPI and report ADRs to IPC so that all generated data can be gathered and examined in one location. The PV field's historical developments, with particular reference to India, are listed in Table 6. Figure 10 displays the PVPI-managed governing body and monitored centers.

Fig 5 : Pharmacovigilance program in India and responsibilities.